Apellis Pharmaceuticals Inc. (APLS) and Rafael Holdings Inc. (NYSEAMERICAN:RFL) Contrasting side by side

Apellis Pharmaceuticals Inc. (NASDAQ:APLS) and Rafael Holdings Inc. (NYSEAMERICAN:RFL) have been rivals in the Biotechnology for quite some time. Below is a review of each business including various aspects such as profitability, analyst recommendations, institutional ownership, risk, dividends, earnings and valuation.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Apellis Pharmaceuticals Inc. N/A 0.00 156.34M -2.77 0.00
Rafael Holdings Inc. 4.46M 68.54 3.28M -0.06 0.00

Demonstrates Apellis Pharmaceuticals Inc. and Rafael Holdings Inc. earnings per share (EPS), top-line revenue and valuation.

Profitability

Table 2 provides Apellis Pharmaceuticals Inc. and Rafael Holdings Inc.’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Apellis Pharmaceuticals Inc. 0.00% -77.1% -60.8%
Rafael Holdings Inc. -73.54% -3% -2.7%

Liquidity

Apellis Pharmaceuticals Inc. has a Current Ratio of 15.2 and a Quick Ratio of 15.2. Competitively, Rafael Holdings Inc.’s Current Ratio is 13 and has 13 Quick Ratio. Apellis Pharmaceuticals Inc.’s better ability to pay short and long-term obligations than Rafael Holdings Inc.

Analyst Ratings

In next table is given Apellis Pharmaceuticals Inc. and Rafael Holdings Inc.’s ratings and recommendations.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Apellis Pharmaceuticals Inc. 0 0 1 3.00
Rafael Holdings Inc. 0 0 0 0.00

Apellis Pharmaceuticals Inc. has a 112.56% upside potential and a consensus target price of $45.

Insider and Institutional Ownership

The shares of both Apellis Pharmaceuticals Inc. and Rafael Holdings Inc. are owned by institutional investors at 53.8% and 35.2% respectively. Insiders owned 0.1% of Apellis Pharmaceuticals Inc. shares. Competitively, Rafael Holdings Inc. has 1.1% of it’s share owned by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Apellis Pharmaceuticals Inc. 2.44% -0.47% 34.54% 27.47% -23.33% 43.52%
Rafael Holdings Inc. -3.82% 14.51% -0.92% 93.51% 93.74% 103.03%

For the past year Apellis Pharmaceuticals Inc. has weaker performance than Rafael Holdings Inc.

Summary

Rafael Holdings Inc. beats Apellis Pharmaceuticals Inc. on 7 of the 10 factors.

Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases. Its lead product candidates include APL-2 and APL-1, to treat paroxysmal nocturnal hemoglobinuria, geographic atrophy, intermediate age-related macular degeneration, and chronic obstructive pulmonary disease. The company develops APL-2 for subcutaneous injection, which is an injection into the tissue under the skin, and for intravitreal injection that is an injection into the eye, as well as APL-1 for inhaled administration. Apellis Pharmaceuticals, Inc. was founded in 2009 and is based in Crestwood, Kentucky.

Rafael Holdings, Inc. holds commercial real estate assets. The company, through its subsidiaries, focuses on the development and commercialization of oncology drugs. Rafael Holdings, Inc. is based in Newark, New Jersey.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.